Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Open accessThe DOI matches its Crossref record; 202 of the 217 references it cites were found in a registry or an index; 71 of the 117 sources its claims cite were checked for support.
Abstract
In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of dementia and one of the first chronic diseases in elderly people. With 55 million people affected, the WHO considers AD to be a disease with public priority. Unfortunately, there are no final cures for this pathology. Treatment strategies are aimed to mitigate symptoms, i.e., acetylcholinesterase inhibitors (AChEI) and the N-Methyl-D-aspartate (NMDA) antagonist Memantine. At present, the best approaches for managing the disease seem to combine pharmacological and non-pharmacological therapies to stimulate cognitive reserve. Over the last twenty years, a number of drugs have been discovered acting on the well-established biological hallmarks of AD, deposition of β-amyloid aggregates and accumulation of hyperphosphorylated tau protein in cells. Although previous efforts disappointed expectations, a new era in treating AD has been working its way recently. The Food and Drug Administration (FDA) gave conditional approval of the first disease-modifying therapy (DMT) for the treatment of AD, aducanumab, a monoclonal antibody (mAb) designed against Aβ plaques and oligomers in 2021, and in January 2023, the FDA granted accelerated approval for a second monoclonal antibody, Lecanemab. This review describes ongoing clinical trials with DMTs and non-pharmacological therapies. We will also present a future scenario based on new biomarkers that can detect AD in preclinical or prodromal stages, identify people at risk of developing AD, and allow an early and curative treatment.
Overview
CoChat Summary
## TL;DR
This is a narrative review of Alzheimer’s disease (AD) treatment beyond symptomatic therapy, focusing on disease-modifying treatments, stem cells, and non-pharmacological interventions. It argues that earlier diagnosis with biomarkers and earlier treatment are key, and it highlights recent antibody approvals such as aducanumab and lecanemab.
## Key findings
- The review states that the estimated number of people with AD dementia is about 50 million worldwide, and that this may rise to 150 million by 2050.
- It says the current symptomatic drugs are acetylcholinesterase inhibitors and memantine, which provide temporary relief but do not cure AD.
- In phase III clinical trials, the authors report 36 agents in the AD pipeline, of which 25% are DMT-biologics, 42% are DMT small molecules, and 7 agents (19% of the total DMTs) are monoclonal antibodies targeting different parts of Aβ.
- The review reports multiple trial outcomes: donanemab slowed cognitive decline by 40% on the iADRS in TRAILBLAZER-ALZ 2; lecanemab produced moderately less decline at 18 months in early AD; gantenerumab failed to meet primary endpoints; and solanezumab failed in completed phase 3 trials.
## Methods
- Narrative literature review of AD treatments “beyond symptomatic therapies,” covering immunotherapy, disease-modifying treatments, stem cells, and non-pharmacological interventions.
- The authors draw on published studies and clinical trial listings from ClinicalTrials.gov; no original patient sample or new dataset is reported.
- Main analysis is descriptive synthesis of trial and preclinical evidence, with discussion of trial design issues, biomarker use, and developmental status of therapies.
## Limitations
- The paper itself does not state formal study limitations; it is a review rather than an empirical study.
- Evident limitation: the conclusions depend on heterogeneous evidence from preclinical studies, phase II/III trials, and trial registries, rather than a systematic meta-analysis or newly collected data.
- Evident limitation: several treatment sections are incomplete or only mention ongoing trials, so for some agents the paper cannot provide outcome data yet.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
46 Valid · 4 Not valid · 20 Not checked · 6 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Supportedcites [4] Selkoe, 2016, The amyloid hypothesis of Alzheimer’s disease at 25 years, EMBO Mol. Med. source
The Introduction describes Aβ aggregation and deposition followed by tau-related changes, neuronal dysfunction, and clinical dementia. The section “Connecting plaques and tangles” also states that Aβ accumulation can lead to progressive tau deposition. Page numbers were not supplied in our copy. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [5] Fontana, 2020, Amyloid-β oligomers in cellular models of Alzheimer’s disease, J. Neurochem. source
- Supportedcites [6] Cline, 2018, The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade, J. Alzheimer’s Dis. source
The Introduction (page unavailable) says Aβ oligomers cause tau pathology, nerve-cell death, and cognitive loss, and describes neuronal damage leading to dementia. The tau-progression section (page unavailable) reports synaptic Aβ oligomers and phosphorylated tau in AD brains. Together, these support the broad paraphrase, although the paper emphasizes Aβ oligomers as the proposed upstream driver. (LLM, conf=0.84)
- Partly supportedcites [7] Hayden, 2013, Amyloid β-protein oligomers and Alzheimer’s disease, Alzheimer’s Res. Ther. sourceExperimental — accuracy not yet measured
The Introduction describes Aβ deposits and oligomers in AD and links loss of cognitive function to synaptic damage and neuronal loss. The ‘Oligomer characterization in vivo’ section reports tau accumulation and cognitive decline together in a mouse model, but the paper does not establish that misfolded Aβ and tau both accumulate in the human AD brain as a single causal cascade leading to dementia. (LLM, conf=0.84)
- Supportedcites [8] Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., and Lewczuk, P. (2018). Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease. Int. J. Mol. Sci., 19. source
The Introduction identifies Aβ plaques and phosphorylated Tau tangles as hallmarks of AD and states that progressive neuronal and synaptic damage leads to cognitive impairment and dementia. Sections 2.6 and 2.8 describe Tau aggregation and Aβ-related pathological processes, supporting the claim’s description of a neurodegenerative cascade. (LLM, conf=0.91)
- Supportedcites [9] Noble, 2016, Amyloid-β Receptors: The Good, the Bad, and the Prion Protein, J. Biol. Chem. source
The Introduction describes Aβ plaques and tau tangles in the AD brain. It also presents the amyloid cascade hypothesis, in which Aβ-driven pathology is followed by cell loss and dementia, and reports an interpretation in which Aβ aggregation triggers tau aggregation and neurodegeneration. This supports the citing sentence as a broad description of the proposed cascade. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Not checked — no full text of the sourcecites [10] Walsh, 2004, Deciphering the molecular basis of memory failure in Alzheimer’s disease, Neuron source
- Partly supportedcites [11] Freir, 2010, Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says therapeutic targeting of Aβ dimers remains attractive because it should prevent formation of toxic pre-fibrillar assemblies. This supports a possible treatment strategy, but the paper does not specify treatment in the early stages of AD or establish that broadly reducing soluble aggregates is practical. (LLM, conf=0.85)
- Supportedcites [12] Lacor, 2004, Synaptic targeting by Alzheimer’s-related amyloid beta oligomers, J. Neurosci. source
The Discussion (page not provided) proposes neutralizing early pathogenic events and reports that antibodies against soluble Aβ species reversed memory loss in mouse models of early AD. It describes the prospects for therapeutic antibodies targeting these assemblies as encouraging, while noting complications with active vaccination. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Not checked — no full text of the sourcecites [10] Walsh, 2004, Deciphering the molecular basis of memory failure in Alzheimer’s disease, Neuron source
- Partly supportedcites [11] Freir, 2010, Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion describes non-fibrillar, water-soluble Aβ as the principal mediators of neurotoxicity, and the Results show that soluble protofibrils inhibit synaptic plasticity. The paper does not directly compare their toxicity with that of monomers or insoluble mature fibrils, so the full comparative claim is not established. (LLM, conf=0.82)
- Partly supportedcites [12] Lacor, 2004, Synaptic targeting by Alzheimer’s-related amyloid beta oligomers, J. Neurosci. sourceExperimental — accuracy not yet measured
The Discussion (page not available) describes soluble Aβ oligomers as neurologically harmful and potent CNS neurotoxins. The ‘Synthetic oligomeric species bind specifically to clustered sites’ section reports that larger oligomers bound hippocampal dendrites whereas a fraction containing monomers and small oligomers did not. The paper does not establish that soluble aggregates are more toxic than insoluble fibrils, and the binding result is not a direct toxicity comparison with monomers. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4].”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 1. Introduction The estimated number of patients with Alzheimer’s disease (AD) dementia is about 50 million worldwide. This number will increase to 150 million by 2050 [1,2]. As amyloid beta (Aβ) deposition can precede cognitive decline, a preclinical stage with neuropathologic changes, positive biomarkers of AD pathology, including Aβ and tau, can last many years or decades without any symptoms. Thus, it can be estimated that there is an even more significant number of persons with an increased risk of progression to cognitive impairment [2,3]. This global scenario urges the need to design new treatment strategies to prevent the onset and progression of AD. AD neuropathology is characterized macroscopically by cerebral cortical thinning and atrophy, where synapsis and neuronal loss contribute to the atrophy [4]. From a microscopic point of view, the hallmarks of AD pathology are neuritic Aβ plaques and neurofibrillary tangles [4]. Misfolded Aβ and tau proteins accumulate in the AD brain in a neurodegenerative cascade leading to cognitive decline and dementia [4,5,6,7,8,9]. Aβ plaques are derived from the β-amyloid precursor protein (APP), which undergoes an alternative proteolytic pathway, in which Aβ peptides are generated by endoproteolytic cleavage of APP by β- and γ-secretase [4,5,6,7,8,9]. The Aβ protein exists in various conformational states, including soluble monomers, soluble aggregates (oligomers, protofibrils), and insoluble fibrils and plaque [4,5,6,7,8,9]. These different forms may mediate different pathogenic events in AD [10]. Among these various forms, soluble Aβ aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble Aβ aggregates could represent a practical treatment approach in the early stages of AD [10,11,12]. AD pathology is a proteinopathy caused by protein misfolding and aggregation [13]. This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15]. A common characteristic of these diseases is the conversion of normally soluble proteins into insoluble fibrillar aggregates [13]. Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (Aβ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α-α-synuclein (αSyn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16]. The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17]. The Aβ oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic Aβ oligomers rather than amyloid plaques as key players in AD pathogenesis [4,5,6,7]. Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of Aβ [4,5,6,7,18]. In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and cognitive loss are the consequences of the Aβ oligomers toxicity on neurons. Low molecular weight Aβ oligomers, which are the most aqueously diffusible, may mediate disruption of neurite integrity and synaptic plasticity [19]. Recently, the physicochemical origin of oligomer toxicity has been deeply studied [16]. Pairs of toxic and non-toxic oligomers have been discovered for Aβ42, alpha-synuclein and other proteinopathies. Common physicochemical properties in the different pairs have been found, including a higher fraction of solvent-exposed hydrophobic residues, which demonstrate a high affinity for biological membranes, resulting in an ability to disrupt them and the capacity to induce cellular dysfunction [16]. In conclusion, solvent-exposed hydrophobic residues appear to be a key shared property of toxic oligomers [16]. Oligomers can also contribute to AD pathogenesis via neuron-to-neuron spreading or by generating new fibrils following neuronal uptake. Aβ oligomers exert their toxicity, promoting a rapid decrease in membrane expression of memory-related receptors, reducing spine density, and promoting synaptic deterioration in cultures of hippocampal neurons [19]. The biological mechanisms that ultimately lead to neuronal cell death and neurodegeneration include membrane perturbation, intracellular Ca2+ influx mediated by N-Methyl-D-aspartate (NMDA) and Adenosine Monophospate (AMP) receptors, mitochondrial dysfunction, reactive oxygen species (ROS) production, lipid peroxidation, an increased caspase-3 response, and aberrant protein−protein interactions [20]. It is worth noting that in the AD drug development pipeline, mAbs are designed to target Aβ oligomers, as demonstrated by Lecanemab. In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21]. Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22,23,24,25]. Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27]. The current hypothesis in AD pathogenesis takes into consideration the early accumulation of Aβ species and plaques, which precedes the spreading of tau, neuronal loss, and clinical manifestations over two decades [22,26,27,28]. The collective body of knowledge suggest that Aβ accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29]. Indeed, evidence shows that tau is significantly elevated in the cerebrospinal fluid (CSF) of AD patients, and its increase is an early event before the onset of the clinical signs [22]. Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31]. In this scenario, the accumulation of Aβ has been considered the primary injury, and therapeutic approaches have been targeted towards Aβ removal. However, the subsequent tau pathology and tau-mediated neurodegeneration recently suggested that tau pathology can progress independently of Aβ accumulation [32]. Tau-targeted therapies as alternatives to Aβ-targeted treatments have recently emerged as potential strategies for treating AD patients [3]. AD disease-modifying strategies are designed to target abnormal Aβ aggregates, clear, and delay or prevent the formation of aggregates [33]. Historically, AD disease-modifying strategies beyond symptomatic medications have relied on (a) anti-Aβ production and aggregation agents, decreasing the synthesis of Aβ, such as β- and γ-secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of Aβ by immunotherapy; (c) anti-tau protein drugs [33,34].
What the sources say
- Supportedcites [4] Selkoe, 2016, The amyloid hypothesis of Alzheimer’s disease at 25 years, EMBO Mol. Med. source
The section “Connecting plaques and tangles” calls plaques and tangles the two canonical lesions of Alzheimer’s disease. The biomarker section likewise refers to them as the two major lesions, and the Abstract identifies neuritic plaques as deposits of amyloid fibrils. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Donanemab significantly slowed the clinical progression in individuals with early symptomatic AD and amyloid and tau pathology.”
§ Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies > 4. State of the Art of AD Disease-Modifying Treatments (DMT)s > 4.1. mAbs Anti-Aβ and Anti-Tau
What the sources say
- Supportedcites [68] Sims, 2023, Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial, JAMA source
The Abstract conclusions state that donanemab significantly slowed clinical progression at 76 weeks among participants with early symptomatic Alzheimer disease and amyloid and tau pathology. The Primary Outcome section also reports statistically significant slowing versus placebo in both the low/medium tau and combined tau populations. (LLM, conf=0.95)
- Could not verifycites [69] Wessels, 2015, A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer’s Disease Rating Scale (iADRS), J. Prev. Alzheimer’s Dis. sourceExperimental — accuracy not yet measured
The Results > Therapeutic Sensitivity passage reports reduced decline with solanezumab in mild AD, not donanemab. Searches for donanemab and for early symptomatic AD with amyloid and tau pathology found no passage in our copy addressing the attributed finding; page numbers were not available. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
33 more claims · 22 with their cited sources checked
Create a free account to see all 76 claims and to verify the 4 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“In particular, the resulting complex, activating ERK and JNK1 kinases, which hyperphosphorylated tau protein, prevented the tau microtubule stabilization and contributed to neuronal dysfunction and degeneration [160,161].”
Cited work 10.1016/j.neurobiolaging.2017.03.016 · retracted 2017-07-01 · notice 10.1016/j.neurobiolaging.2017.03.016 · this paper published 2023-09-09
Citations
Cites
1 retracted
Wang, H.-Y., Lee, K.-C., Pei, Z., Khan, A., Bakshi, K. P., & Burns, L. H. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.016 · Cited by 55 · cited 2×
“In particular, the resulting complex, activating ERK and JNK1 kinases, which hyperphosphorylated tau protein, prevented the tau microtubule stabilization and contributed to neuronal dysfunction and degeneration [160,161].”
BackgroundRetractedNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 7×
“The A β oligomer hypothesis, supported by in vitro, in vivo, and ex vivo models, points to the toxic A β oligomers rather than amyloid plaques as key players in AD pathogenesis [4–7].”
BackgroundInfluentialLecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575 · cited 2×
“This number will increase to 150 million by 2050 [1,2].”
BackgroundCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of A β [4–7 , 18].”
BackgroundActivation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274 · cited 1×
“Among them, MAPK signaling is activated in the early stages of immune activation [132].”
BackgroundNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
MethodStern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943 · cited 1×
“They aim to stimulate the cognitive reserve as the brain’s ability to actively solve a pathological process through the remodeling of brain networks, allowing the offset of the impairment due to the disease [185].”
BackgroundDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932 · cited 2×
“The results of TRAILBLAZER-ALZ 2 show that diagnosing and treating people earlier in the course of AD may lead to greater clinical benefit [68,69].”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“…of other mechanisms such as inflammation [95], imbalance among production and removal of ROS [96], mitochondrial dysfunction [82], in addition to the β -amyloid cascade [97] and the deficiency of central cholinergic neurotransmitters [98] on which are based most of anti-AD drugs so far approved.”
BackgroundThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · cited 1×
“In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22–25].”
BackgroundMetabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802 · cited 1×
“Instead, in the very early phases of AD, a significant loss of σ 1R occurs in the brain [115,116].”
BackgroundRosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784 · cited 1×
“Tertomotide Tertomotide or GV1001, originally designed as a cancer vaccine, is a 16 amino acid peptide comprising a sequence from the human enzyme of the human telomerase reverse transcriptase catalytic subunit (hTERT) [88].”
BackgroundPhysiological basis of transcranial direct current stimulation
Stagg, C. J., & Nitsche, M. A. (2011) · The Neuroscientist · doi:10.1177/1073858410386614 · Cited by 1,719 · cited 1×
“Among the non-invasive brain stimulation techniques, tDCS is the most safe, tolerable and low-cost to administer for a long time at home [198].”
BackgroundMicroglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710 · cited 1×
“As mentioned earlier, primed microglia represent the main player in AD neuroinflam-mation [131].”
BackgroundEpidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651 · cited 1×
“Another alternative treatment strategy is to target neural circuit dysfunctions, known as parts of AD pathological processes that contribute to the brain network disruption that could cause cognitive impairment [194].”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27].”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
Budd Haeberlein, S., Aisen, P. S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.30 · Cited by 1,367
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · cited 4×
“Clinical studies of AN-1792 reached phase 2a, in which 372 patients with probable AD (mild to moderate) were enrolled [38].”
BackgroundInfluentialToxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251 · cited 2×
“AD pathology is a proteinopathy caused by protein misfolding and aggregation [13].”
BackgroundSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242 · cited 2×
“Tauopathies are neurodegenerative diseases characterized by a common pathological hallmark: aggregated tau deposition in the brain [26,27].”
BackgroundA Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 1×
“In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22–25].”
BackgroundDeciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207 · cited 2×
“Among these various forms, soluble A β aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble A β aggregates could represent a practical treatment approach in the early stages of AD [10–12].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
BackgroundSelf-citationBlood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045 · cited 1×
“Indeed, blood-based biomarkers for AD could pave the way in supporting the diagnosis of AD in clinical practice and in improving the development of clinical trials for the earliest stages of AD [53–55].”
BackgroundRebok, G. W., Ball, K., Guey, L. T., Jones, R. N., Kim, H., King, J. W., Marsiske, M., Morris, J. N., Tennstedt, S. L., Unverzagt, F. W., et al. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12607 · Cited by 965 · cited 1×
“…speed of processing training (SPT), significantly delays the onset of clinically defined MCI or dementia across three years, based on the results of a previous study, ACTIVE, where reasoning and speed, but not memory, training resulted in improved targeted cognitive abilities for 10 years [188].”
ResultSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · cited 1×
“Among these various forms, soluble A β aggregates are more toxic than monomers or insoluble fibrils; thus, reducing these soluble A β aggregates could represent a practical treatment approach in the early stages of AD [10–12].”
BackgroundIncreased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950 · cited 1×
“This probably explains why up to 81% of AD patients also suffer from impaired glucose tolerance (IGT) and Type 2 diabetes (T2D) [135].”
BackgroundSpector, A., Thorgrimsen, L., Woods, B., Royan, L., Davies, S., Butterworth, M., & Orrell, M. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.183.3.248 · Cited by 876 · cited 1×
“This includes multifaceted approaches that do not act specifically on cognitive mechanisms, but using reminiscence therapy and Reality Orientation Therapy (ROT), they aim to enhance general cognitive and social functioning with comparable effectiveness to the AChE inhibitors to slow down cognitive decline [186].”
BackgroundThe Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“In addition, Aducanumab, as with other mAbs, can induce radiographic features known as AD-related imaging abnormalities with edema (ARIA-E) or hemorrhage (ARIA-H) [66].”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · cited 2×
“Unlike with aducanumab, the companies filed directly under the accelerated-approval pathway using phase 2b data, which showed drastic plaque reduction [75].”
BackgroundMethodβ-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D'Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 822 · cited 1×
“The major knowledge and research on the molecular mechanisms of AD pathogenesis led to the study with interest of the α7 nicotinic acetylcholine receptor (α7nAChR) that binds with high-affinity the soluble amyloid β1-42(Aβ42) triggering the protein tau hyperphosphorylation [158,159].”
BackgroundSmith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012244 · Cited by 813 · cited 1×
“…dietary approaches in terms of nutrition supplementation, such as combined formulation of specific active ingredients or probiotics, or nutritional guidance, such as fasting intermitting or Mediterranean diet, ameliorate both cognition and function of prodromal and mild AD patients [200–202].”
BackgroundThe secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Mediterranean Diet and Mild Cognitive Impairment
Scarmeas, N., Stern, Y., Mayeux, R., Manly, J. J., Schupf, N., & Luchsinger, J. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.536 · Cited by 757
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685 · cited 2×
“However, this small molecule was dismissed after the failure of the phase 3 clinical trial without a previous real phase 2 trial to establish the long-term safety of verubecestat [43,44].”
BackgroundProteostasis impairment in protein-misfolding and -aggregation diseases
Hipp, M. S., Park, S.-H., & Hartl, F. U. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.05.003 · Cited by 663 · cited 1×
“The protein homeostasis system typically prevents amyloid accumulation, which declines in ageing [17].”
BackgroundHe, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645 · cited 1×
“…that A β accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29].”
BackgroundSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619 · cited 2×
“In light of this evidence, two large phase III studies were started, with three arms (high dose, low dose, placebo) [57–60].”
BackgroundEpileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590 · cited 1×
“Furthermore, seizures are more frequent in aged people with AD than in those without dementia [109].”
BackgroundAmyloid-β-independent regulators of tau pathology in Alzheimer disease
van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580
Anti-Amyloid-β Monoclonal Antibodies for Alzheimer’s Disease: Pitfalls and Promise
van Dyck, C. H. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.010 · Cited by 568
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557 · cited 2×
“In light of this evidence, two large phase III studies were started, with three arms (high dose, low dose, placebo) [57–60].”
BackgroundKnopman, D. S., Jones, D. T., & Greicius, M. D. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12213 · Cited by 524 · cited 1×
“On 22 October 2019, Biogen declared that the interim futility analysis was wrong and that subsequent analysis of a more extensive data set showed that EMERGE had met its primary endpoint regarding the high, but not the low dose [62,63].”
BackgroundBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Bahar-Fuchs, A., Clare, L., & Woods, B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003260.pub2 · Cited by 507
Aggrephagy: Selective Disposal of Protein Aggregates by Macroautophagy
Lamark, T., & Johansen, T. (2012) · International Journal of Cell Biology · doi:10.1155/2012/736905 · Cited by 497 · cited 1×
“Au-tophagy undoubtedly represents a crucial process in neural development and homeostasis through which harmful and/or redundant macromolecules are cleared thanks to lysosomal pathways [142,143].”
BackgroundRevisiting the cholinergic hypothesis in the development of Alzheimer's disease
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 486 · cited 1×
“…of other mechanisms such as inflammation [95], imbalance among production and removal of ROS [96], mitochondrial dysfunction [82], in addition to the β -amyloid cascade [97] and the deficiency of central cholinergic neurotransmitters [98] on which are based most of anti-AD drugs so far approved.”
BackgroundAlzheimer’s disease drug development pipeline: 2023
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12385 · Cited by 477
Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins
Martínez, P., & Blasco, M. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3025 · Cited by 468
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 2×
“Donanemab (N3pG) is a humanized mAb developed from mouse mE8-IgG2a [67].”
BackgroundMechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431 · cited 1×
“This antibody can disassemble and degrade amyloid plaques by recruiting microglia and activating phagocytosis [71,72].”
BackgroundTrial of solanezumab in preclinical Alzheimer's disease
Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2305032 · Cited by 429 · cited 1×
“In a more recent phase 3 trial (NCT02008357), solanezumab failed to meet primary and secondary outcomes, as the drug did not slow cognitive decline in preclinical AD or reduce the risk of progression to symptomatic AD [80].”
BackgroundMasitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421 · cited 1×
“Masitinib is a tyrosine kinase inhibitor that interferes with the survival, migration, and activity of MCs and microglia, showing a neuroprotective effect in neurodegenerative diseases and concentrating on the CNS at a therapeutically relevant amount [127,128].”
BackgroundTotal and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · cited 1×
“Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31].”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85–87].”
Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm
Yin, K., Wang, S., & Zhao, R. C. (2019) · Biomarker Research · doi:10.1186/s40364-019-0159-x · Cited by 380 · cited 1×
“Their BBB permeability and low immunogenicity certainly make them appealing regarding drug delivery [180,181].”
BackgroundImmune modulation by mesenchymal stem cells
Rasmusson, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.019 · Cited by 374 · cited 1×
“Third, as they do not expose on their surface the MHC-2, they are less immunogenic and challenging to reject from the immune system, especially since they can suppress T cell activation, modulating the immune function with an immunosuppressive effect [169,170].”
BackgroundCoric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., Richter, R. W., Soininen, H., Thein, S., Shiovitz, T., Pilcher, G., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374 · cited 2×
“However, this small molecule was dismissed after the failure of the phase 3 clinical trial without a previous real phase 2 trial to establish the long-term safety of verubecestat [43,44].”
BackgroundMethodMelatonin Prevents Death of Neuroblastoma Cells Exposed to the Alzheimer Amyloid Peptide
Pappolla, M. A., Sos, M., Omar, R. A., Bick, R. J., Hickson-Bick, D. L. M., Reiter, R. J., Efthimiopoulos, S., & Robakis, N. K. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01683.1997 · Cited by 359 · cited 1×
“In addition, melatonin inhibits the β -fibrillogenesis with neuroprotective and antioxidant activities in vitro and in vivo AD models [153,154].”
BackgroundReview: Systemic inflammation andAlzheimer's disease
Holmes, C. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01307.x · Cited by 356 · cited 1×
“Although the genetic susceptibility, numerous findings support the involvement in AD pathogenesis of other mechanisms such as inflammation [95], imbalance among production and removal of ROS [96], mitochondrial dysfunction [82], in addition to the β-amyloid cascade [97] and the deficiency of central cholinergic neurot…”
BackgroundTolar, M., Abushakra, S., Hey, J. A., Porsteinsson, A., & Sabbagh, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00663-w · Cited by 354 · cited 1×
“Not only are monoclonal antibodies developed against β-amyloid, but there is also a small molecule agent, named ALZ-801, that prevents neurotoxic Aβ formation with no plaque interaction [163].”
BackgroundOxidative Stress Signaling in Alzheimers Disease
Su, B., Wang, X., Nunomura, A., Moreira, P., Lee, H.-G., Perry, G., Smith, M., & Zhu, X. (2008) · Current Alzheimer Research · doi:10.2174/156720508786898451 · Cited by 344 · cited 1×
“…findings support the involvement in AD pathogenesis of other mechanisms such as inflammation [95], imbalance among production and removal of ROS [96], mitochondrial dysfunction [82], in addition to the β -amyloid cascade [97] and the deficiency of central cholinergic neurotransmitters [98] on…”
BackgroundMatsubara, E., Bryant‐Thomas, T., Pacheco Quinto, J., Henry, T. L., Poeggeler, B., Herbert, D., Cruz‐Sanchez, F., Chyan, Y., Smith, M. A., Perry, G., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01654.x · Cited by 332 · cited 1×
“In addition, melatonin inhibits the β -fibrillogenesis with neuroprotective and antioxidant activities in vitro and in vivo AD models [153,154].”
BackgroundGuzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323 · cited 1×
“In particular, out of only five drugs approved, four of them are AchEI to stimulate cholinergic neurotransmission (Tacrine, retired due to hepatoxicity, Donepezil, Galantamine, Rivastigmine), while Memantine acts as the antagonist of NMDA receptors in order to activate them [99,100].”
BackgroundChen, H.-X., Liang, F.-C., Gu, P., Xu, B.-L., Xu, H.-J., Wang, W.-T., Hou, J.-Y., Xie, D.-X., Chai, X.-Q., & An, S.-J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2473-5 · Cited by 319 · cited 1×
“Extracellular vesicles released by MSCs are part of the secretome, and their usage as therapeutic tools has already been reported in many neurological disease models [178,179].”
BackgroundLiu, R.-Y., Zhou, J.-N., van Heerikhuize, J., Hofman, M. A., & Swaab, D. F. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5394 · Cited by 304 · cited 1×
“Melatonin, a hormone mainly synthesized and secreted in the pineal gland, decreases during ageing and even more in AD patients, likely leading to cognitive impairments [151,152].”
BackgroundWang, L., Benzinger, T. L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., McConathy, J., Cairns, N. J., Fagan, A. M., Morris, J. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2078 · Cited by 293 · cited 1×
“…that A β accumulation represents an upstream pathophysiological event and may function as a trigger/facilitator of downstream molecular pathways, including tau misfolding, tau-mediated toxicity, accumulation in tangles, and tau spreading that leads to cortical neurodegeneration [24,26,27,29].”
BackgroundLuchsinger, J. A., Perez, T., Chang, H., Mehta, P., Steffener, J., Pradabhan, G., Ichise, M., Manly, J., Devanand, D. P., & Bagiella, E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150493 · Cited by 285 · cited 1×
“Glucose metabolism amelioration in the Central Nervous System (CNS) is supposed to improve the cognitive decline of early and late amnestic Mild Cognitive Impairment patients or prevent the cognitive decline in obese people [3,105,106].”
BackgroundDendritic Tau in Alzheimer’s Disease
Ittner, A., & Ittner, L. M. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.003 · Cited by 278 · cited 4×
“In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22–25].”
BackgroundInfluentialAmyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276 · cited 2×
“Elevated levels of oligomers have been associated with AD, as they are found in AD brains and are considered the most toxic and pathogenic form of A β [4–7 , 18].”
BackgroundInsulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
Neth, B. J., & Craft, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00345 · Cited by 272 · cited 1×
“Therefore, targeting glucose metabolism and insulin resistance could be an important step in over-coming mitochondrial dysfunction and cholesterol metabolism failures in ageing or AD [83].”
BackgroundTau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies
Chang, C.-W., Shao, E., & Mucke, L. (2021) · Science · doi:10.1126/science.abb8255 · Cited by 263
Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils
O'Nuallain, B., Freir, D. B., Nicoll, A. J., Risse, E., Ferguson, N., Herron, C. E., Collinge, J., & Walsh, D. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3537-10.2010 · Cited by 259
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein
Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., & Hooper, N. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.702704 · Cited by 256
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255 · cited 1×
“The long-term effects of active immunization with the same A β 42 synthetic peptide were studied, and the results after 6 years showed the clearance of amyloid plaques but no evidence of increased survival rate or improvement of severe dementia [39].”
BackgroundAlzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241 · cited 3×
“Consequently, the updated use recommendations of Aducanumab emphasize the importance of detecting past medical conditions that may predispose the patient to ARIA or may increase the likelihood of ARIA complications [47].”
BackgroundMethodWhy do so many clinical trials of therapies for Alzheimer's disease fail?
Anderson, R. M., Hadjichrysanthou, C., Evans, S., & Wong, M. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32399-1 · Cited by 228 · cited 1×
“Since 2003, FDA has approved no new small molecules, despite many long and expensive trials [107].”
BackgroundNeuronal Aggregates: Formation, Clearance, and Spreading
Lim, J., & Yue, Z. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.02.002 · Cited by 222 · cited 1×
“Au-tophagy undoubtedly represents a crucial process in neural development and homeostasis through which harmful and/or redundant macromolecules are cleared thanks to lysosomal pathways [142,143].”
BackgroundInsulin-resistant brain state: The culprit in sporadic Alzheimer's disease?
Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.01.001 · Cited by 212 · cited 1×
“Glucose metabolism amelioration in the Central Nervous System (CNS) is supposed to improve the cognitive decline of early and late amnestic Mild Cognitive Impairment patients or prevent the cognitive decline in obese people [3,105,106].”
BackgroundAducanumab: Appropriate Use Recommendations Update
Cummings, J., Rabinovici, G. D., Atri, A., Aisen, P., Apostolova, L. G., Hendrix, S., Sabbagh, M., Selkoe, D., Weiner, M., & Salloway, S. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.34 · Cited by 196
Designing the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191 · cited 2×
“In the new era of AD treatment marked by the availability of mAbs that can modulate disease progression and cognitive decline, the need for the future is the possibility of detecting AD in preclinical or prodromal stages [205].”
BackgroundLee, J. K., Jin, H. K., & Bae, J.-S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.059 · Cited by 189 · cited 1×
“In AD treatment, the MSCs bone marrow-derived (BM-MSCs) are particularly interesting since they can accelerate microglia activation, reduce amyloid-β deposition and ameliorate cognitive abilities in AD mouse models [171].”
Backgroundα7 Nicotinic Acetylcholine Receptors Mediate β-Amyloid Peptide-induced Tau Protein Phosphorylation
Wang, H.-Y., Li, W., Benedetti, N. J., & Lee, D. H. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212532200 · Cited by 185 · cited 1×
“The major knowledge and research on the molecular mechanisms of AD pathogenesis led to the study with interest of the α 7 nicotinic acetylcholine receptor ( α 7nAChR) that binds with high-affinity the soluble amyloid β 1-42(A β 42) triggering the protein tau hyperphosphorylation [158,159].”
BackgroundRole of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183 · cited 2×
“However, in March 2019, Eisai and Biogen announced the termination of all ongoing aducanumab trials due to the failure of interim analysis [61,62].”
BackgroundBaird, A., & Samson, S. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2014.11.028 · Cited by 180 · cited 1×
“Furthermore, reminiscence therapy takes advantage of different sensorial stimuli to evoke and retrieve past and recent memories, such as musical and visual stimulation [187].”
BackgroundCSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180 · cited 1×
“Furthermore, both total and phosphorylated tau (p-tau) are increased in the CSF of AD patients and can predict the progression of the disease [22,30,31].”
BackgroundBuccellato, F. R., D’Anca, M., Fenoglio, C., Scarpini, E., & Galimberti, D. (2021) · Antioxidants · doi:10.3390/antiox10091353 · Cited by 179 · cited 3×
“This association may in part be due to systemic mitochondrial dysfunction that is common to these pathologies [82].”
BackgroundInfluentialSelf-citationDeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172 · cited 1×
“Nilotinib, a c-Abl tyrosine kinase inhibitor already approved for the treatment of chronic myeloid leukemia, has been shown to prevent degeneration in murine models of AD [146,147].”
BackgroundLow density of sigma1 receptors in early Alzheimer’s disease
Mishina, M., Ohyama, M., Ishii, K., Kitamura, S., Kimura, Y., Oda, K.-I., Kawamura, K., Sasaki, T., Kobayashi, S., Katayama, Y., et al. (2008) · Annals of Nuclear Medicine · doi:10.1007/s12149-007-0094-z · Cited by 172 · cited 1×
“Instead, in the very early phases of AD, a significant loss of σ 1R occurs in the brain [115,116].”
BackgroundLecanemab in Early Alzheimer’s Disease
(2023) · New England Journal of Medicine · doi:10.1056/nejmc2301380 · Cited by 172
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163 · cited 1×
“GLP1-RAs is known for its neuroprotective action, and more recent results have emerged, showing a potential benefit in people with AD [85–87].”
Relationship between Exercise and Alzheimer’s Disease: A Narrative Literature Review
Meng, Q., Lin, M.-S., & Tzeng, I.-S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00131 · Cited by 158 · cited 1×
“Physical exercises are reported to improve cognition and quality of life, and home-based exercises seemed to improve balance and fear of falling and executive functions [190–192].”
BackgroundPassive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
Deep brain stimulation in Parkinson’s disease: meta-analysis of randomized controlled trials
Perestelo‐Pérez, L., Rivero‐Santana, A., Pérez-Ramos, J., Serrano-Pérez, P., Panetta, J. C., & Hilarión, P. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7254-6 · Cited by 144
Villard, V., Espallergues, J., Keller, E., Vamvakides, A., & Maurice, T. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379286 · Cited by 139 · cited 1×
“anti-amnesic and neuroprotective action [118].”
Brain Stimulation in Alzheimer's Disease
Chang, C.-H., Lane, H.-Y., & Lin, C.-H. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00201 · Cited by 139 · cited 2×
“The brain stimulation approaches that include, for example, deep brain stimulation (DBS) or transcranial direct current stimulation (tDCS), use electricity in order to “turn on” or to “turn off specific brain activities acting with invasive tools, as the DBS, or not, as the tDCS [195].”
BackgroundRoberts, M., Sevastou, I., Imaizumi, Y., Mistry, K., Talma, S., Dey, M., Gartlon, J., Ochiai, H., Zhou, Z., Akasofu, S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-0884-2 · Cited by 135 · cited 2×
“E2814 is a humanized mAb that recognizes an HVPGG peptide epitope in the microtubule-binding domain near the mid-domain of tau [76].”
BackgroundNilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease
Turner, R. S., Hebron, M. L., Lawler, A., Mundel, E. E., Yusuf, N., Starr, J. N., Anjum, M., Pagan, F., Torres‐Yaghi, Y., Shi, W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25775 · Cited by 126 · cited 1×
“In a previous phase II study, Nilotinib was safe and well tolerated in mild to moderate AD, penetrating the BBB and achieving pharmacologically relevant levels in the CSF [150].”
BackgroundThinking laterally about neurodegenerative proteinopathies
Golde, T. E., Borchelt, D. R., Giasson, B. I., & Lewis, J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66029 · Cited by 124 · cited 1×
“This process is common to other neurodegenerative diseases, such as Parkinson’s disease, Huntington’s disease, light chain amyloidosis, and spongiform encephalopathies [14,15].”
BackgroundMicroglial priming in Alzheimer’s disease
Li, J.-W., Zong, Y., Cao, X.-P., Tan, L., & Tan, L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.22 · Cited by 122 · cited 2×
“The effort to find an innovative non-amyloid-based compound acting on neuroinflam-mation could be another treatment option since the growing body of evidence supports the involvement of the neuroimmune system, mast cells (MCs), and microglia in AD onset and progression [125,126].”
BackgroundFluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122 · cited 1×
“In this regard, experimental data supports a pathogenic mechanism in which AD neuropathology and Tau, a microtubule-associated protein, is highly expressed in neurons and has been implicated in the pathogenesis of AD and other neurodegenerative diseases called “tauopathies” [19,20,22–25].”
BackgroundSelf-citationExtracellular signal‐regulated kinase regulates microglial immune responses in Alzheimer’s disease
Chen, M. J., Ramesha, S., Weinstock, L. D., Gao, T., Ping, L., Xiao, H., Dammer, E. B., Duong, D. D., Levey, A. I., Lah, J. J., et al. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24829 · Cited by 120 · cited 1×
“In preclinical AD mouse models, ERK1 and ERK2 represent the stronger upregulated phosphoproteins in the MAPK family and are increased in post-mortem human AD brains [133].”
BackgroundDisease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119 · cited 2×
“As previously anticipated, passive immunotherapy is considered the most effective approach to preventing and treating AD (see Figure 1) [36,37].”
BackgroundDisease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117 · cited 2×
“…strategies beyond symptomatic medications have relied on (a) anti-A β production and aggregation agents, decreasing the synthesis of A β , such as β - and γ -secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of A β by immunotherapy; (c) anti-tau protein drugs [33,34].”
BackgroundAmyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
The implications of different approaches to define AT(N) in Alzheimer disease
Mattsson-Carlgren, N., Leuzy, A., Janelidze, S., Palmqvist, S., Stomrud, E., Strandberg, O., Smith, R., & Hansson, O. (2020) · Neurology · doi:10.1212/wnl.0000000000009485 · Cited by 114
Cooney, D. S., Wimmers, E. G., Ibrahim, Z., Grahammer, J., Christensen, J. M., Brat, G. A., Wu, L. W., Sarhane, K. A., Lopez, J., Wallner, C., et al. (2016) · Scientific Reports · doi:10.1038/srep31306 · Cited by 110 · cited 1×
“Moreover, they can substitute damaged neurons, recovering several impaired functions and differentiating in Schwann cells regenerating neurons [172,173].”
BackgroundBateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109 · cited 2×
“Gantenerumab preferentially interacts with the aggregated form of A β and was developed for subcutaneous administration [71–73].”
BackgroundPadala, K. P., Padala, P. R., Lensing, S. Y., Dennis, R. A., Bopp, M. M., Roberson, P. K., & Sullivan, D. H. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170120 · Cited by 107
Dubois, B., López-Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., Venger, O., Vermersch, P., Moussy, A., Mansfield, C. D., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01169-x · Cited by 107 · cited 1×
“The positive results of a previous phase IIb/III study (AB09004; NCT01872598) revealed the positive effects of Masitinib, which slowed down cognitive impairment in mild to moderate AD patients [130].”
ResultHe, P., Ouyang, X.-P., Zhou, S., Yin, W., Tang, C., Laudon, M., & Tian, S. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2013.04.009 · Cited by 106 · cited 1×
“On this basis, the Piromelatine (or Neu-P11) agent acting as an agonist of melatonin and serotonin receptors has been demonstrated to improve memory and neuronal and cognitive impairments in preclinical studies [155].”
BackgroundHammond, T. C., Xing, X., Wang, C., Ma, D., Nho, K., Crane, P. K., Elahi, F., Ziegler, D. A., Liang, G., Cheng, Q., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1079-x · Cited by 106 · cited 1×
“In this view, an appropriate treatment approach for AD may include an early target, such as A β and tau, and a later and continuous restoration of brain metabolic function to prevent cognitive function [84].”
BackgroundLeoutsakos, J.-M. S., Yan, H., Anderson, W. S., Asaad, W. F., Baltuch, G., Burke, A., Chakravarty, M. M., Drake, K. E., Foote, K. D., Fosdick, L., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180121 · Cited by 104 · cited 1×
“Even if in several murine models, DBS has been shown to improve visual-spatial memory, in a phase II study with 2 years of follow-up on mild AD patients, DBS targeting the fornix was safe and well tolerated but with no clinical benefits [197].”
BackgroundGarcía-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104 · cited 1×
“Since their counterbalancing action on the cholinergic imbalance of the disease, these classes of drugs attenuate symptoms, providing temporary relief from mild to moderate to severe AD [101].”
BackgroundKishita, N., Backhouse, T., & Mioshi, E. (2020) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988719856690 · Cited by 103 · cited 1×
“Music therapy, phototherapy, and aromatherapy, alone or combined, have resulted in positive outcomes in cognition, emotion, and behavior [189].”
BackgroundLa Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98
Yin, T., Liu, Y., Ji, W., Zhuang, J., Chen, X., Gong, B., Chu, J., Liang, W., Gao, J., & Yin, Y. (2023) · Theranostics · doi:10.7150/thno.81860 · Cited by 98 · cited 1×
“Indeed, MSCs can be engineered to release EVs containing siRNA or miRNA against β - amyloid plaques directly (see Figure 1) [182].”
BackgroundTelomere-independent functions of telomerase in nuclei, cytoplasm, and mitochondria
Chiodi, I., & Mondello, C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00133 · Cited by 97 · cited 1×
“These independent-telomeric functions of hTERT are associated with cellular proliferation, stem cell mobilization, anti-apoptotic, and antioxidant effects through mitochondrial stabilization, transcriptional regulation, and effects on the Wnt signaling pathway [89,90].”
BackgroundCellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
Dehghan, E., Zhang, Y., Saremi, B., Yadavali, S., Hakimi, A., Dehghani, M., Goodarzi, M., Tu, X., Robertson, S., Lin, R., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02394-3 · Cited by 92 · cited 1×
“…efficacy based on his action on antioxidative stress mechanisms, such as activation of the Nrf2 signaling pathway, increase of mitochondria respiration capacity and adenosine triphosphate production, activation of autophagy, which facilitates intracellular aggregate clearance [102].”
BackgroundGoldoni, R., Dolci, C., Boccalari, E., Inchingolo, F., Paghi, A., Strambini, L. M., Galimberti, D., & Tartaglia, G. M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101587 · Cited by 91 · cited 1×
“These ideal BMs should be peripheral and non-invasive (blood/saliva) [206,207].”
BackgroundSelf-citationFrontzkowski, L., Ewers, M., Brendel, M., Biel, D., Ossenkoppele, R., Hager, P., Steward, A., Dewenter, A., Römer, S., Rubinski, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32592-7 · Cited by 89 · cited 1×
“Tau aggregation is a promising target for AD DMT, as it is a hallmark pathology of AD that correlates with younger AD symptom onset and can progress independently from amyloid pathology [32,167].”
BackgroundFerrendelli, J. A., French, J. A., Leppik, I. E., Morrell, M. J., Herbeuval, A.-F., Han, J. Y., & Magnus, L. (2003) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2003.09.007 · Cited by 87 · cited 1×
“This is the case of the anti-seizure AGB101 (low-dose extended-release Levetiracetam) preferentially prescribed for epilepsy in older people due to its lack of drug–drug interactions [108].”
BackgroundWessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86 · cited 2×
“The results of TRAILBLAZER-ALZ 2 show that diagnosing and treating people earlier in the course of AD may lead to greater clinical benefit [68,69].”
BackgroundPrecision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project
Toups, K., Hathaway, A., Gordon, D., Chung, H., Raji, C. A., Boyd, A., Hill, B. D., Hausman-Cohen, S., Attarha, M., Chwa, W. J., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215707 · Cited by 85 · cited 1×
“A previous pilot study revealed improvement in all outcome cognitive measures and in MRI brain volumetrics [203], supporting the performance of a large randomized clinical trial started in June and not still in the enrollment phase.”
MethodReading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84
Mesenchymal Stem Cell Therapy for Alzheimer’s Disease
Hernández, A. E., & García, E. (2021) · Stem Cells International · doi:10.1155/2021/7834421 · Cited by 84
Two decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H., Han, Y., Kong, L., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 83 · cited 1×
“The complexity in the pathogenesis and in the interactions with related genes and proteins makes the research of drugs against AD that can have a long-term effect or even provide a cure challenging [94].”
BackgroundAmyloid Formation in Light Chain Amyloidosis
Ramírez-Alvarado, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611212220007 · Cited by 82
Haeberlein, S. B., von Hehn, C., Tian, Y., Chalkias, S., Muralidharan, K. K., Chen, T., Wu, S., Skordos, L., Nisenbaum, L., Rajagovindan, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.047259 · Cited by 81 · cited 2×
“…of Aducanumab by the FDA for the treatment of mild cognitive impairment due to AD and mild AD dementia on 7 June 2021. plaques and oligomers The approval of the fi rst mAb against AD was given without a de fi nitively proven clinical bene fi t based on its e ff ects on AD biomarkers [47,62,64,65].”
BackgroundChapter 5 Autophagic Clearance of Aggregate‐Prone Proteins Associated with Neurodegeneration
Sarkar, S., Ravikumar, B., & Rubinsztein, D. C. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(08)04005-6 · Cited by 79 · cited 1×
“Indeed, the clearance of A β deposits exploits mainly the autophagic pathways, as well as an autophagy dysfunction, which is associated with the increased release of β -amyloid [144,145].”
BackgroundTsai, S.-Y. A., Pokrass, M. J., Klauer, N. R., Nohara, H., & Su, T.-P. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422001112 · Cited by 77 · cited 1×
“In addition, σ 1R is involved in controlling protein tau phosphorylation [117].”
BackgroundAbushakra, S., Porsteinsson, A., Scheltens, P., Sadowsky, C., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Wang, P., et al. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.26 · Cited by 75 · cited 1×
“In mild AD patients, the clinical benefits of tramiprosate treatment were more pronounced in homozygosis (APOE4/4) carriers rather than in heterozygosis (APOE4/3) or non-carriers (APOE3/3), in whom there was no benefit [166].”
BackgroundVermersch, P., Brieva-Ruiz, L., Fox, R. J., Paul, F., Ramio-Torrenta, L., Schwab, M., Moussy, A., Mansfield, C., Hermine, O., Maciejowski, M., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001148 · Cited by 74 · cited 1×
“Masitinib is a tyrosine kinase inhibitor that interferes with the survival, migration, and activity of MCs and microglia, showing a neuroprotective effect in neurodegenerative diseases and concentrating on the CNS at a therapeutically relevant amount [127,128].”
BackgroundMesenchymal Stem Cell Therapy and Alzheimer’s Disease: Current Status and Future Perspectives
Kim, J., Lee, Y., Lee, S., Kim, K., Song, M., & Lee, J. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200219 · Cited by 73 · cited 3×
“Second, they are less prone to transformation into neoplastic cells [169].”
BackgroundPark, H.-H., Lee, K.-Y., Kim, S., Lee, J. W., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Lee, S.-H., & Koh, S.-H. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.015 · Cited by 72 · cited 1×
“In rat neuronal stem cells, GV1001 blocked Aβ oligomer-induced toxicity and increased the survival of neuronal cells exposed to oxidative stress [91,92].”
BackgroundRamírez-Rodríguez, G., Vega-Rivera, N. M., Benítez-King, G., Castro-García, M., & Ortíz-López, L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.09.045 · Cited by 71
Hey, J. A., Kocis, P., Hort, J., Abushakra, S., Power, A., Vyhnálek, M., Yu, J. Y., & Tolar, M. (2018) · CNS Drugs · doi:10.1007/s40263-018-0554-0 · Cited by 71 · cited 2×
“ALZ-801 is a prodrug of tramiprosate with the same major metabolite, 3-sulfopropanoic acid (3-SPA), physiologically present in the human adult brain and in the CSF of subjects with cognitive deficits due to AD and other neurodegenerative disorders [164].”
BackgroundNasiri, E., Alizadeh, A., Roushandeh, A. M., Gazor, R., Hashemi-Firouzi, N., & Golipoor, Z. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00421-4 · Cited by 68 · cited 2×
“When treated with melatonin, these MSCs attenuate symptoms of AD associated with naïve AT-MSCs [175].”
BackgroundAbushakra, S., Porsteinsson, A., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Hendrix, S., Wang, P., Shen, L., et al. (2016) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2016.115 · Cited by 64 · cited 1×
“Interestingly, tramiprosate showed the highest efficacy linked to the presence of the ε4 allele of the apolipoprotein E gene (APOE4), a critical risk factor for AD onset [165].”
BackgroundReducing Amyloid-Related Alzheimer's Disease Pathogenesis by a Small Molecule Targeting Filamin A
Wang, H.-Y., Bakshi, K., Frankfurt, M., Stucky, A., Goberdhan, M., Shah, S. M., & Burns, L. H. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.0354-12.2012 · Cited by 63 · cited 3×
“In particular, the resulting complex, activating ERK and JNK1 kinases, which hyperphosphorylated tau protein, prevented the tau microtubule stabilization and contributed to neuronal dysfunction and degeneration [160,161].”
BackgroundMatt, E., Dörl, G., & Beisteiner, R. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12245 · Cited by 63 · cited 1×
“This novel ultrasound-based stimulation allows targeting precise regions of interest, and it is reported to improve depression in AD patients [199].”
BackgroundNon-drug Therapies for Alzheimer’s Disease: A Review
Li, X., Ji, M., Zhang, H., Liu, Z., Chai, Y., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00416-x · Cited by 60 · cited 1×
“They can be distinguished into cognitive-oriented interventions, physical exercise interventions, brain stimulation, nutrition supplementations and/or diet restrictions, as well as music therapy and phototherapy [183].”
BackgroundWu, C., Wang, I., Chiang, P., Wang, L., Shen, C.-K. J., & Tsai, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0122-x · Cited by 59 · cited 1×
“Moreover, they can substitute damaged neurons, recovering several impaired functions and differentiating in Schwann cells regenerating neurons [172,173].”
BackgroundSigma-1 receptor: a potential therapeutic target for traumatic brain injury
Shi, M., Chen, F., Chen, Z., Yang, W., Yue, S., Zhang, J., & Chen, X. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.685201 · Cited by 58 · cited 1×
“The σ 1R, primarily present in many tissues, is broadly expressed in CNS cells [111].”
BackgroundAn increase of sigma1 receptors in the aged monkey brain
Kawamura, K., Kimura, Y., Tsukada, H., Kobayashi, T., Nishiyama, S., Kakiuchi, T., Ohba, H., Harada, N., Matsuno, K., Ishii, K., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00152-5 · Cited by 56
Ryan, S. T., Hosseini‐Beheshti, E., Afrose, D., Ding, X., Xia, B., Grau, G. E., Little, C. B., McClements, L., & Li, J. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063023 · Cited by 55 · cited 1×
“Their BBB permeability and low immunogenicity certainly make them appealing regarding drug delivery [180,181].”
BackgroundLimbocker, R., Errico, S., Barbut, D., Knowles, T. P. J., Vendruscolo, M., Chiti, F., & ZASLOFF, M. A. (2022) · Natural Product Reports · doi:10.1039/d1np00042j · Cited by 55 · cited 1×
“In addition, a promising class of small molecules is aminosterols, which prevent the binding of toxic oligomers Aβ40, Aβ42, and αSyn to cells, thereby eliminating their toxicity [21].”
BackgroundWischik, C. M., Bentham, P., Gauthier, S., Miller, S., Kook, K., & Schelter, B. O. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.63 · Cited by 55 · cited 1×
“Hydromethylthionine mesylate (HMTM) is a tau aggregation inhibitor designed to reduce tau aggregation pathology in AD [168].”
BackgroundTakeuchi, D., Sato, N., Shimamura, M., Kurinami, H., Takeda, S., Shinohara, M., Suzuki, S., Kojima, M., Ogihara, T., & Morishita, R. (2008) · Gene Therapy · doi:10.1038/sj.gt.3303094 · Cited by 51 · cited 1×
“Existing literature supports the neurotrophic and neuroprotective role of HGF/MET signaling in several mouse models of different neurological disorders, including A β -induced cognitive impairment mice, where the HGF/MET implementation reduced disease progression and restore function [120,121].”
BackgroundKoike, H., Ishida, A., Shimamura, M., Mizuno, S., Nakamura, T., Ogihara, T., Kaneda, Y., & Morishita, R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302810 · Cited by 50 · cited 1×
“Existing literature supports the neurotrophic and neuroprotective role of HGF/MET signaling in several mouse models of different neurological disorders, including A β -induced cognitive impairment mice, where the HGF/MET implementation reduced disease progression and restore function [120,121].”
BackgroundImmunotherapy for Alzheimer’s disease
Morgan, D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s348 · Cited by 50 · cited 2×
“As previously anticipated, passive immunotherapy is considered the most effective approach to preventing and treating AD (see Figure 1) [36,37].”
BackgroundLi, T., Martin, E., Abada, Y.-S., Boucher, C., Cès, A., Youssef, I., Fenaux, G., Forand, Y., Legrand, A., Nachiket, N., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200466 · Cited by 50 · cited 1×
“In preclinical studies, Masitinib exerted a synaptoprotective effect by inhibiting MCs and restoring normal spatial learning performance [129].”
BackgroundÖhman, H., Savikko, N., Strandberg, T., Kautiainen, H., Raivio, M., Laakkonen, M.-L., Tilvis, R., & Pitkälä, K. H. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000445712 · Cited by 49
Park, H.-H., Yu, H.-J., Kim, S., Kim, G., Choi, N.-Y., Lee, E.-H., Lee, Y. J., Yoon, M.-Y., Lee, K.-Y., & Koh, S.-H. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.05.022 · Cited by 49 · cited 1×
“In rat neuronal stem cells, GV1001 blocked A β oligomer-induced toxicity and increased the survival of neuronal cells exposed to oxidative stress [91,92].”
BackgroundLimbocker, R., Cremades, N., Cascella, R., Tessier, P. M., Vendruscolo, M., & Chiti, F. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00045 · Cited by 48 · cited 1×
“Each proteinopathy is characterized by different fibrillar aggregates, such as amyloid-β (A β ) plaques and neurofibrillary tangles of tau in AD, Lewy bodies of α - α -synuclein ( α Syn) in PD, or amyloid deposits of an immunoglobulin light chain in AL [16].”
BackgroundOmega-3 fatty acids are associated with blood-brain barrier integrity in a healthy aging population
Barnes, S., Chowdhury, S., Gatto, N. M., Fraser, G. E., & Lee, G. J. (2021) · Brain and Behavior · doi:10.1002/brb3.2273 · Cited by 47 · cited 1×
“Recent findings showed significant correlations between long-chain omega-3 levels and blood–brain barrier (BBB) integrity and cognition, providing evidence of a possible mechanism by which omega-3 may contribute to brain health [103].”
BackgroundSleep physiology and disorders in aging and dementia
(2019) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-804766-8.00026-1 · Cited by 46 · cited 1×
“This multimodal drug was developed for treating insomnia that AD patients exhibit severely, and it is associated with worsened cognitive and memory capacities [156].”
BackgroundProfile of gantenerumab and its potential in the treatment of Alzheimer's disease
Nisticò, R., Novakovic, D., Feligioni, M., Scaccianoce, S., Piccinin, S., Mercuri, N. B., Nicoletti, F., Caruso, A., Schepisi, C., & Errico, F. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s53401 · Cited by 44 · cited 2×
“It was selected because it can bind both the N-terminal and central amino acids of Aβ [70].”
BackgroundGuanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer’s disease
Liu, H., Luo, K., & Luo, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-21256-6 · Cited by 42 · cited 1×
“These findings are in keeping with clinical literature showing low levels of MET protein in the brains of AD patients and the MET gene as the most downregulated by transcriptome analysis [122,123].”
ResultD’Anca, M., Fenoglio, C., Buccellato, F. R., Visconte, C., Galimberti, D., & Scarpini, E. A. (2021) · Cells · doi:10.3390/cells10071733 · Cited by 42 · cited 1×
“Extracellular vesicles released by MSCs are part of the secretome, and their usage as therapeutic tools has already been reported in many neurological disease models [178,179].”
BackgroundSelf-citationKoh, S.-H., Kwon, H. S., Choi, S. H., Jeong, J. H., Na, H. R., Lee, C. N., Yang, Y., Lee, A. Y., Lee, J.-H., Park, K. W., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00803-w · Cited by 39 · cited 1×
“In a completed phase 2 study conducted in Korea, GV1001 showed significant improvement from the baseline of Severe Impairment Battery score at Week 24 and demonstrated a clinically acceptable safety profile in patients with moderate to severe AD [93].”
BackgroundAdlimoghaddam, A., Odero, G. G., Glazner, G., Turner, R. S., & Albensi, B. C. (2021) · Aging and disease · doi:10.14336/ad.2020.0910 · Cited by 38 · cited 1×
“Another work investigated the role of Nilotinib in brain mitochondrial dysfunction, highlighting how this drug could ameliorate mitochondrial function in the brain astroglia of an AD mouse model [149].”
BackgroundCai, Z., Zhou, Y., Liu, Z., Ke, Z., & Tian, F. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84755 · Cited by 37 · cited 1×
“Indeed, the clearance of A β deposits exploits mainly the autophagic pathways, as well as an autophagy dysfunction, which is associated with the increased release of β -amyloid [144,145].”
Background“Real world” eligibility for aducanumab
Canevelli, M., Rossi, P. D., Astrone, P., Consorti, E., Vanacore, N., & Cesari, M. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17390 · Cited by 36 · cited 1×
“…too extensive to see any effect, thus patients with very mild dementia should be treated rather than moderately–severely impaired; (2) no biomarker was required as eligibility criteria for inclusion; (3) lack of informative outcome measures or surrogate biomarkers of clinical response [46–49].”
BackgroundBurns, L. H., Pei, Z., & Wang, H. (2023) · Drug Development Research · doi:10.1002/ddr.22085 · Cited by 35 · cited 1×
“The tau hyperphosphorylation is prevented, allowing microtubule stabilization [162].”
BackgroundAge-related changes of the binding of [3H]SA4503 to sigma1 receptors in the rat brain
Ishiwata, K., Kobayashi, T., Kawamura, K., & Matsuno, K. (2003) · Annals of Nuclear Medicine · doi:10.1007/bf02988264 · Cited by 33 · cited 1×
“Interestingly, the levels of this receptor are maintained or increased in the normal-aged brain of animal models [112,113], and σ 1R increases with healthy ageing have also been reported in human studies [114].”
BackgroundKhan, R. S., Dine, K., Luna, E., Ahlem, C., & Shindler, K. S. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-14672 · Cited by 33
Down‐regulation of MET in hippocampal neurons of Alzheimer's disease brains
Hamasaki, H., Honda, H., Suzuki, S. O., Hokama, M., Kiyohara, Y., Nakabeppu, Y., & Iwaki, T. (2014) · Neuropathology · doi:10.1111/neup.12095 · Cited by 33 · cited 1×
“These findings are in keeping with clinical literature showing low levels of MET protein in the brains of AD patients and the MET gene as the most downregulated by transcriptome analysis [122,123].”
ResultLambert, W. S., Carlson, B. J., Formichella, C. R., Sappington, R. M., Ahlem, C., & Calkins, D. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00045 · Cited by 31 · cited 2×
“In neurodegeneration murine models, NE3107 has been shown to reduce inflammation-driven ERK, the primed microglia, and amyloid precursor protein, and it selectively inhibits NF-kB [137,138].”
BackgroundSen, A., Akinola, M., Tai, X. Y., Symmonds, M., Davis Jones, G., Mura, S., Galloway, J., Hallam, A., Chan, J. Y. C., Koychev, I., et al. (2021) · Trials · doi:10.1186/s13063-021-05404-4 · Cited by 30 · cited 1×
“In the early stages of AD, the drug is supposed to reduce neuronal hyperactivity A β -induced fighting the memory impairment and slowing the disease progression [110].”
BackgroundNobili, A., Barbera, L. L., & D’Amelio, M. (2021) · Autophagy · doi:10.1080/15548627.2021.1909409 · Cited by 29 · cited 1×
“In particular, Nilotinib was able to reduce A β and phospho-c-Abl levels, restoring autophagic flow in Tg2576 dopaminergic neurons of several brain regions [148].”
BackgroundAmen, D. G., Harris, W. S., Kidd, P. M., Meysami, S., & Raji, C. A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170281 · Cited by 25 · cited 1×
“Furthermore, lower omega-3 fatty acid levels are correlated to reduced brain blood flow to regions important for learning, memory, depression, and dementia [104].”
BackgroundLessons that can be learnt from the failure of verubecestat in Alzheimer’s disease
Doggrell, S. A. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1654998 · Cited by 24 · cited 1×
“Verubecestat, administered in patients with mild-to-moderate AD, was not beneficial and increased adverse effects [45].”
BackgroundFunakoshi, H., & Nakamura, T. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211795659982 · Cited by 23 · cited 1×
“In this context, hepatocyte growth factor (HGF), highly active in most CNS cell types, is a critical neurotrophic factor that, upon binding the mesenchymal epithelial transition factor (MET) receptor tyrosine kinase, elicits mitogenic, mitogenic, and morphogenic functions [119].”
BackgroundReading, C. L., Frincke, J. M., & White, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032147 · Cited by 21 · cited 1×
“The compound NE3107 (formerly HE3286) is a derivative of β-androstenetriol, an adrenal sterol derived from the human metabolome, is blood–brain permeable, binds ERK1/2, and acts as an anti-inflammatory insulin sensitizer [136].”
BackgroundIntermittent Fasting: A Promising Approach for Preventing Vascular Dementia
Yoon, G., & Song, J. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.1.1 · Cited by 20 · cited 1×
“…dietary approaches in terms of nutrition supplementation, such as combined formulation of specific active ingredients or probiotics, or nutritional guidance, such as fasting intermitting or Mediterranean diet, ameliorate both cognition and function of prodromal and mild AD patients [200–202].”
BackgroundJohnston, J. L., Reda, S. M., Setti, S. E., Taylor, R. W., Berthiaume, A.-A., Walker, W. E., Wu, W., Moebius, H. J., & Church, K. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01325-5 · Cited by 18 · cited 1×
“Furthermore, the prodrug and clinical candidate developed later, Fosfogonimen-ton, confirmed in vivo its positive effects, reverting cognitive deficits [124].”
BackgroundEffects of walking on sundown syndrome in community‐dwelling people with Alzheimer’s disease
Shih, Y., Pai, M., Lin, H., Sung, P., & Wang, J. (2019) · International Journal of Older People Nursing · doi:10.1111/opn.12292 · Cited by 17 · cited 1×
“Due to the apparent complexity of performing physical exercises, especially in patients with severe AD, a good strategy could be to work on personal habits to deliver physical interventions, such as regular walking [193].”
BackgroundAducanumab for Alzheimer’s Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies
Yuksel, J. M., Noviasky, J., & Britton, S. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.329 · Cited by 16
Zhang, Q., Guo, S., Zhang, X., Tang, S. H., Wang, L., Xiaojuan, H., Shao, W., Cong, L., & Du, Y. (2015) · Gene · doi:10.1016/j.gene.2015.02.011 · Cited by 15 · cited 1×
“Furthermore, A β induces the ERK-dependent serine phosphorylation of the insulin receptor substrate (IRS) in astrocytes, inhibiting its ability to transduce insulin signals to downstream targets [134].”
BackgroundPfizer abandons research into Alzheimer’s and Parkinson’s diseases
Hawkes, N. (2018) · BMJ · doi:10.1136/bmj.k122 · Cited by 15 · cited 2×
“It is worth mentioning that the period of 2017–2018 marks the termination of various trials and the abandonment of the investment in drugs against AD by Pfizer and other companies [46].”
BackgroundThe most valuable player or the tombstone: is tau the correct target to treat Alzheimer’s disease?
Younes, K., & Sha, S. J. (2023) · Brain · doi:10.1093/brain/awad151 · Cited by 15 · cited 1×
“As N-terminally targeted anti-tau antibodies have shown no efficacy in clinical trials, more potent mid-region antibodies have been designed to interfere with the propagation of pathogenic aggregates of tau [81].”
BackgroundBiglari, N., Mehdizadeh, A., Mastanabad, M. V., Gharaeikhezri, M. H., Afrakoti, L. G. M. P., Pourbala, H., Yousefi, M., & Soltani‐Zangbar, M. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154541 · Cited by 15 · cited 1×
“Indeed, the MSC secretome contains numerous bioactive molecules able to attenuate AD symptoms and indirectly contribute to Aβ-amyloid plaque degradation [177].”
BackgroundSchneider, L. S., Laudon, M., Nir, T., Caceres, J., Ianniciello, G., Capulli, M., & Zisapel, N. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.61 · Cited by 13 · cited 1×
“On the other hand, the non-carriers improved significantly with piromelatine compared to the placebo on the ADAS-Cog14 and PSQI with piromelatine [157].”
Background(2004) · Evidence-Based Mental Health · doi:10.1136/ebmh.7.1.28 · Cited by 12 · cited 1×
“Therefore, another element that should be considered is caregiver burden, which affects physical and psychological health more than non-caregivers [204].”
BackgroundDubois, B., López‑Arrieta, J., Lipschitz, S., Doskas, T., Spiru, L., Moroz, S., Venger, O., Vermersch, P., Moussy, A., Mansfield, C. D., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01230-9 · Cited by 10
S3‐01‐01: Prevention report from Alzheimer's disease international (ADI)
Prince, M. J. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.07.214 · Cited by 9 · cited 1×
“This number will increase to 150 million by 2050 [1,2].”
BackgroundHorsager, J., Fedorova, T. D., Berge, N. V. D., Klinge, M. W., Knudsen, K., Hansen, A. K., Alstrup, A. K. O., Krogh, K., Gormsen, L. C., & Borghammer, P. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419838509 · Cited by 9 · cited 1×
“Interestingly, the levels of this receptor are maintained or increased in the normal-aged brain of animal models [112,113], and σ 1R increases with healthy ageing have also been reported in human studies [114].”
Background
Cited by
Oxidative stress–mediated neuroinflammation in Alzheimer’s disease
Firdous, S. M., Khan, S. A., & Maity, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03188-3 · Cited by 98
Fołta, J., Rzepka, Z., & Wrześniok, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115177 · Cited by 56
“…treatment of Alzheimer’s disease; i /inhibitors of the enzyme cholinesterase, i.e., donepezil, rivastigmine, or galantamine, and ii /N-methyl-D-aspartate antagonists, i.e., memantine, which are only effective in treating the symptoms of the disease but do not cure or prevent the disease [88,114].”
Ureña-Vacas, I., Belén, A. D. L. R. M., Serrano, D. R., & González‐Burgos, E. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100235 · Cited by 46
Arroyo-Pacheco, N., Sarmiento-Blanco, S., Vergara-Cadavid, G., Castro-Leones, M., & Contreras‐Puentes, N. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102620 · Cited by 44
Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis)
Wanionok, N. E., Morel, G. R., & Fernández, J. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102408 · Cited by 32
Metadata
- Authors
- Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D.
- Affiliations
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy
- Corresponding author
- Buccellato, Francesca R.
- D’Anca, Marianna
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-09-09
- Volume
- 24
- Issue
- 18
- Pages
- 13900
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10531090
- OpenAlex
- W4386602162
- Cited by
- 94
- References
- 217
- Citations by year
- 2026: 26 · 2025: 35 · 2024: 31 · 2023: 2
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Funders
- Italian Ministry of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying therapy, aducanumab, lecanemab, acetylcholinesterase inhibitors, memantine, amyloid plaques, tau hyperphosphorylation, cognitive reserve, non-pharmacological treatment, biomarkers, prodromal Alzheimer's disease, clinical trials
- MeSH terms
- Acetylcholinesterase, Aged, Alzheimer Disease, Antibodies, Monoclonal, Humans, Memantine, United States, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
